Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240916 · ClinicalTrials.gov registry record
Ontogeny of Measles Immunity in Infants
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 750
- Enrollment target
NCT00240916: Completed study, sponsored by Stanford University.
NCT00240916 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 750 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00240916 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 750 participants
- Enrollment target
Study Summary
This is an immunogenicity study evaluating the development of the immune response of healthy infants following primary vaccination with Attenuvax at 6 or 9 months of age compared with responses in 12 month-old infants receiving MMR-II. Responses of infants receiving an early two dose measles vaccine regimen with the first dose given at 6 or 9 months followed by a second dose administered at 12 months will also be compared to infants given a single dose at 12 months of age (Table 2). The current approved regimen for measles vaccination is a first vaccination at 12-15 months and a subsequent vaccination at school entry. A secondary endpoint of this study will be to assess the safety of measles vaccine administered as Attenuvax at 6 or 9 months of age and in an early two dose measles vaccine regimen with Attenuvax administered at 6 or 9 months followed by MMR-II at 12 months of age.
Interventions
- BIOLOGICAL Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)
- BIOLOGICAL MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 1993-07 |
| Est. Completion | 2013-07 |
What the finished NCT00240916 record still lists
NCT00240916 is an observational study that tracks outcomes without assigning an intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous) is the first listed.
NCT00240916 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00240916 about?
NCT00240916 is a clinical study titled "Ontogeny of Measles Immunity in Infants". This is an immunogenicity study evaluating the development of the immune response of healthy infants following primary vaccination with Attenuvax at 6 or 9 months of age compared with responses in 12 month-old infants receiving MMR-II. Responses of infants receiving an early two dose measles vaccine...
What is the current status of trial NCT00240916?
This trial is currently completed. The enrollment target is 750 participants. The study started on 1993-07. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00240916?
The interventions under investigation include: Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous) (BIOLOGICAL), MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00240916?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia